Clonidine topical gel - BioDelivery Sciences International

Drug Profile

Clonidine topical gel - BioDelivery Sciences International

Alternative Names: ARC-4558

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Arcion Therapeutics
  • Developer BioDelivery Sciences International
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 01 Feb 2017 BioDelivery Sciences returns back worldwide licensing rights for clonidine topical gel to Arcion Therapeutics
  • 13 Dec 2016 Discontinued - Phase-III for Diabetic neuropathies in USA due to lack of efficacy (Topical)
  • 01 Nov 2016 BioDelivery Sciences completes a phase IIb trial for Diabetic neuropathy in USA (NCT02643251)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top